Coronavirus Infection - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Coronavirus Infection - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Coronavirus Infection - Pipeline Review, H2 2014', provides an overview of the Coronavirus Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Coronavirus Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Coronavirus Infection Overview 6
Therapeutics Development 7
Pipeline Products for Coronavirus Infection - Overview 7
Pipeline Products for Coronavirus Infection - Comparative Analysis 8
Coronavirus Infection - Therapeutics under Development by Companies 9
Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 10
Coronavirus Infection - Pipeline Products Glance 11
Early Stage Products 11
Unknown Stage Products 12
Coronavirus Infection - Products under Development by Companies 13
Coronavirus Infection - Products under Investigation by Universities/Institutes 14
Coronavirus Infection - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Hemispherx Biopharma, Inc. 16
Humabs BioMed SA 17
Inovio Pharmaceuticals, Inc. 18
NanoViricides, Inc. 19
Novavax, Inc. 20
Coronavirus Infection - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
coronavirus vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
EMER-IT - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
interferon alfa-n3 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
interferon beta-1a - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MERS-COV - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MERS-CoV Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
middle east respiratory syndrome coronavirus vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibody for MERS and SARS - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit Viral Protease for Viral Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccine for Respiratory and Infectious Diseases - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Coronavirus Infection - Recent Pipeline Updates 42
Coronavirus Infection - Dormant Projects 46
Coronavirus Infection - Product Development Milestones 47
Featured News & Press Releases 47
Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products under Development for Coronavirus Infection, H2 2014 7
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Coronavirus Infection - Pipeline by AstraZeneca PLC, H2 2014 15
Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H2 2014 16
Coronavirus Infection - Pipeline by Humabs BioMed SA, H2 2014 17
Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 18
Coronavirus Infection - Pipeline by NanoViricides, Inc., H2 2014 19
Coronavirus Infection - Pipeline by Novavax, Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Coronavirus Infection Therapeutics - Recent Pipeline Updates, H2 2014 42
Coronavirus Infection - Dormant Projects, H2 2014 46